Literature DB >> 25857287

Hypoxia-inducible factors in cancer stem cells and inflammation.

Gong Peng1, Yang Liu2.   

Abstract

Hypoxia-inducible factors (HIF) mediate metabolic switches in cells in hypoxic environments, including those in both normal and malignant tissues with limited supplies of oxygen. Paradoxically, recent studies have shown that cancer stem cells (CSCs) and activated immune effector cells exhibit high HIF activity in normoxic environments and that HIF activity is critical in the maintenance of CSCs as well as the differentiation and function of inflammatory cells. Given that inflammation and CSCs are two major barriers to effective cancer therapy, targeting HIF may provide a new approach to developing such treatments.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer immunotherapy; dendritic cells; leukemia-initiating cells; myeloid-derived suppressor cells; tumor microenvironment; tumor-associated macrophages

Mesh:

Substances:

Year:  2015        PMID: 25857287      PMCID: PMC4461458          DOI: 10.1016/j.tips.2015.03.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  119 in total

1.  Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1alpha by the von Hippel-Lindau tumor suppressor gene product.

Authors:  Teresa Pereira; Xiaowei Zheng; Jorge L Ruas; Keiji Tanimoto; Lorenz Poellinger
Journal:  J Biol Chem       Date:  2002-12-04       Impact factor: 5.157

2.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

3.  Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Authors:  Tyler J Curiel; Shuang Wei; Haidong Dong; Xavier Alvarez; Pui Cheng; Peter Mottram; Roman Krzysiek; Keith L Knutson; Ben Daniel; Maria Carla Zimmermann; Odile David; Matthew Burow; Alan Gordon; Nina Dhurandhar; Leann Myers; Ruth Berggren; Akseli Hemminki; Ronald D Alvarez; Dominique Emilie; David T Curiel; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2003-04-21       Impact factor: 53.440

4.  Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Authors:  Christine C Hudson; Mei Liu; Gary G Chiang; Diane M Otterness; Dawn C Loomis; Fiona Kaper; Amato J Giaccia; Robert T Abraham
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

Review 5.  The roles of FLT3 in hematopoiesis and leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

6.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein.

Authors:  Keiichi Kondo; Jeff Klco; Eijiro Nakamura; Mirna Lechpammer; William G Kaelin
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

7.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma.

Authors:  Jodi K Maranchie; James R Vasselli; Joseph Riss; Juan S Bonifacino; W Marston Linehan; Richard D Klausner
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

8.  BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

Authors:  Matthias Mayerhofer; Peter Valent; Wolfgang R Sperr; James D Griffin; Christian Sillaber
Journal:  Blood       Date:  2002-07-18       Impact factor: 22.113

9.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways.

Authors:  James B Brugarolas; Francisca Vazquez; Archana Reddy; William R Sellers; William G Kaelin
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

10.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene.

Authors:  Katrina M Comerford; Timothy J Wallace; Jörn Karhausen; Nancy A Louis; Michael C Montalto; Sean P Colgan
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  45 in total

Review 1.  Clonal cooperativity in heterogenous cancers.

Authors:  Hengbo Zhou; Deepika Neelakantan; Heide L Ford
Journal:  Semin Cell Dev Biol       Date:  2016-08-28       Impact factor: 7.727

2.  Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L.

Authors:  Chengli Song; Qiang Xu; Kui Jiang; Guangyu Zhou; Xuebin Yu; Lina Wang; Yuting Zhu; Liping Fang; Zhe Yu; Jiing-Dwan Lee; Shi-Cang Yu; Qingkai Yang
Journal:  Oncotarget       Date:  2015-10-20

Review 3.  Targeting cancer stem cells from a metabolic perspective.

Authors:  Yao-An Shen; Siao-Cian Pan; I Chu; Ruo-Yun Lai; Yau-Huei Wei
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-26

Review 4.  Self-Sustained Regulation or Self-Perpetuating Dysregulation: ROS-dependent HIF-YAP-Notch Signaling as a Double-Edged Sword on Stem Cell Physiology and Tumorigenesis.

Authors:  Chin-Lin Guo
Journal:  Front Cell Dev Biol       Date:  2022-06-14

Review 5.  Hypoxia inducible factor down-regulation, cancer and cancer stem cells (CSCs): ongoing success stories.

Authors:  Anthony R Martin; Cyril Ronco; Luc Demange; Rachid Benhida
Journal:  Medchemcomm       Date:  2016-10-19       Impact factor: 3.597

Review 6.  3D Cell Culture in a Self-Assembled Nanofiber Environment.

Authors:  Yi Wen Chai; Eu Han Lee; John D Gubbe; John H Brekke
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

Review 7.  Cancer stem cells and strategies for targeted drug delivery.

Authors:  Jin Cao; Shubhmita Bhatnagar; Jiawei Wang; Xueyong Qi; Swayam Prabha; Jayanth Panyam
Journal:  Drug Deliv Transl Res       Date:  2020-10-23       Impact factor: 5.671

Review 8.  Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets.

Authors:  Elena Codrici; Ana-Maria Enciu; Ionela-Daniela Popescu; Simona Mihai; Cristiana Tanase
Journal:  Stem Cells Int       Date:  2016-02-10       Impact factor: 5.443

Review 9.  Hypoxia and Hypoxia-Inducible Factors in Leukemias.

Authors:  Margaux Deynoux; Nicola Sunter; Olivier Hérault; Frédéric Mazurier
Journal:  Front Oncol       Date:  2016-02-26       Impact factor: 6.244

10.  Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.

Authors:  Changhwan Yoon; Kevin K Chang; Jun Ho Lee; William D Tap; Charles P Hart; M Celeste Simon; Sam S Yoon
Journal:  Oncotarget       Date:  2016-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.